AnaptysBio Inc. (ANAB)
NASDAQ: ANAB
· Real-Time Price · USD
22.21
-0.35 (-1.55%)
At close: May 30, 2025, 3:59 PM
22.23
0.09%
After-hours: May 30, 2025, 04:20 PM EDT
-1.55% (1D)
| Bid | 19 |
| Market Cap | 652.54M |
| Revenue (ttm) | 111.87M |
| Net Income (ttm) | -140.62M |
| EPS (ttm) | -5.14 |
| PE Ratio (ttm) | -4.32 |
| Forward PE | -4.52 |
| Analyst | Buy |
| Ask | 23 |
| Volume | 514,244 |
| Avg. Volume (20D) | 738,262 |
| Open | 22.48 |
| Previous Close | 22.56 |
| Day's Range | 21.50 - 22.59 |
| 52-Week Range | 12.21 - 41.31 |
| Beta | -0.20 |
About ANAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ANAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ANAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+9.54%
AnaptysBio shares are trading higher after the com...
Unlock content with
Pro Subscription
3 months ago
+30.45%
AnaptysBio shares are trading higher after the company announced statistically significant week 12 data from the Phase 2b trial of rosnilimab in moderate-to-severe rheumatoid arthritis.
